Recruiting
Phase 3

Ibrutinib

Sponsor:

Janssen Research & Development, LLC

Code:

NCT01804686

Conditions

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Mantle Cell Lymphoma

Follicular Lymphoma

Diffuse Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-18. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-09-17.